Cascadian Therapeutics, Inc.
DelistedCIK 1412067fmd_10QMESY7DN8KQBXJQG3MT1H7RMServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2017, 32 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 0 | 0 | – | – | – | – | – | – |
| Research and development | 6 | 12 | 18 | 22 | 33 | 42 | 23 | 27 | 44 |
| Total operating expenses | 13 | 20 | 25 | 28 | 41 | 51 | 33 | 65 | 58 |
| Operating income | (11) | (19) | (25) | (28) | (41) | (51) | (33) | (65) | (58) |
| Interest expense | – | – | 1 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | (6) | 4 | (18) | 25 | 2 | 1 | 0 | 0 | 1 |
| Income before taxes | (17) | (16) | (43) | (3) | (39) | (50) | (33) | (65) | (57) |
| Income tax expense | 0 | (0) | – | 0 | 0 | 0 | 0 | (7) | – |
| Net income from continuing operations | (17) | (16) | – | (3) | (39) | (50) | (33) | (58) | – |
| Net income | (17) | (16) | (43) | (3) | (39) | (50) | (33) | (58) | (57) |
| Net income to common shareholders | – | (16) | (43) | (3) | (39) | (50) | (33) | (60) | (58) |